Search
for
Sort by
Research 871–900 of 1000+
- Amyopathic dermatomyositis presenting as severe alopecia and prominent eyelid edema: a case report and literature review
- CD27 and IL-35 as diagnostic biomarkers in alopecia areata: First evidence of association with pathogenic scalp bacterial infections
- Association of Serum IL-17A and IL-23 Levels With Alopecia Areata: A Cross-Sectional Comparative Study
- Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
- Psychometric validation of the Spanish alopecia areata–life impact questionnaire
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- TREATMENT OF ALOPECIA AREATA WITH ORAL METHYLPREDNISOLONE COMBINED WITH FRACTIONAL MICRONEEDLE RADIOFREQUENCY
- Alopecia Areata Associated with Dupilumab: A Case Report and Literature Review
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
- Role of microneedling in treatment of alopecia areata
- Development of a Spectrophotometric Method to determination Minoxidil by Diazotization-Coupling reaction with Sulfanilic acid
- Patient Validation of Estimation of Health Utility Values in Alopecia Areata
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Clinical and demographic factors associated with nail involvement in adult alopecia areata patients at Al-Kadhmia teaching hospital, Baghdad, 2023
- Clinical evaluation and treatment response in Patients with non-scarring alopecia: A Prospective Study of 200 Cases
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Depression among Alopecia Areata Patients: Prevalence and associated factors in a Tunisian sample
- Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Risk factors for the development of and outcomes after diagnosis of autoimmune alopecia areata in patients with inflammatory bowel diseases
- Evaluación de la seguridad de minoxidil oral a dosis bajas en el tratamiento de la alopecia
- The evaluation of IL-4 intron 3 VNTR and TNF-α (rs1799964) gene polymorphisms in Egyptian patients with Alopecia Areata: a case-control study
- Comparative Efficacy of Topical Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata (AA)
- Alopecia areata - risk factors, prevention possibilites and therapeutical options
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
- ASSESSMENT OF SERUM LEVELS OF ANTIGLIADIN ANTIBODIES (IGG AND IGA) IN PATIENTS WITH ALOPECIA AREATA AND THEIR RELATION TO SEVERITY OF THE DISEASE